Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?

Authors

  • Anne Couture
  • Mounsif Azizi
  • Daniel Taussky
  • Michael McCormack

DOI:

https://doi.org/10.5489/cuaj.4426

Abstract

18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (18F-FDG PET/CT) is a widely used diagnostic tool for whole-body imaging, and incidental prostatic uptake occurs in approximately 1% of patients undergoing the exam. Is 18F-FDG PET/CT a reliable screening tool for prostate cancer? Should these patients undergo transrectal ultrasound (TRUS)-guided prostate biopsies? Studies have indicated that 18F-FDG PET/CT has a low positive predictive value for prostate cancer and is not recommended for screening;1 however, other studies suggest that when a discrete focal 18F-FDG uptake is discovered without coincidental calcification, particularly in the peripheral zone of the prostate, further clinical evaluation is recommended. We present two patients with incidental 18F-FDG PET/CT prostatic uptake who were found to have high-grade prostate cancer. Although 18F-FDG PET/CT has not been determined to be a reliable screening tool for prostate cancer, patients with incidental 18F-FDG uptake in the prostate should be referred for urological evaluation.

Downloads

Download data is not yet available.

Downloads

Published

2017-07-11

How to Cite

Couture, A., Azizi, M., Taussky, D., & McCormack, M. (2017). Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?. Canadian Urological Association Journal, 11(7), E318–20. https://doi.org/10.5489/cuaj.4426

Issue

Section

Residents' Room